Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
0.734
+0.073 (11.10%)
Mar 12, 2025, 2:35 PM EST - Market open
Prelude Therapeutics Employees
Prelude Therapeutics had 131 employees as of December 31, 2024. The number of employees increased by 3 or 2.34% compared to the previous year.
Employees
131
Change (1Y)
3
Growth (1Y)
2.34%
Revenue / Employee
$54,688
Profits / Employee
-$993,539
Market Cap
40.51M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 131 | 3 | 2.34% |
| Dec 31, 2023 | 128 | 6 | 4.92% |
| Dec 31, 2022 | 122 | 6 | 5.17% |
| Dec 31, 2021 | 116 | 48 | 70.59% |
| Dec 31, 2020 | 68 | - | - |
PRLD News
- 2 days ago - Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 - GlobeNewsWire
- 7 days ago - Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies - GlobeNewsWire
- 3 months ago - Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - GlobeNewsWire
- 4 months ago - Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium - GlobeNewsWire
- 5 months ago - Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium - GlobeNewsWire
- 6 months ago - Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial - GlobeNewsWire
- 6 months ago - Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024 - GlobeNewsWire